Prognostic Indicators as Provided by the EPIC ClearView
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the
 EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale
 that characterizes trends consistent with known diagnoses identified by medical doctors.
 Specifically, the investigators hypothesize that the organ system involving any of a series
 of known active diagnoses will be identified in the EPIC ClearView Response Scale report with
 the intention of providing potential triage capabilities.
Inclusion Criteria:

 Five Diagnosis Group:

 1. Sex: Male or Female

 2. Age range: 18 to 85

 3. Qualifying medical diagnoses (5 diagnosis groups)

 - For potential subjects presenting with one of the five qualifying diagnoses, the
 patient presents with confirmed active medical diagnoses affecting the following
 systems or organs:

 -  Cardiovascular system: coronary artery disease, left sided congestive heart
 failure with EF <50%, valvular heart disease, atrial fibrillation, and
 hypertension

 -  Kidney: pyelonephritis, acute renal failure, or chronic renal failure stages II-V

 -  Liver: viral hepatitis, alcoholic hepatitis, steatohepatitis, or cirrhosis

 -  Pulmonary system: asthma, COPD, bronchitis, emphysema, or pneumonia

 -  Gastrointestinal/Endocrine: inflammatory bowel disease (including Crohn's
 disease, ulcerative colitis, or diverticulitis), peptic ulcer disease, IBS,
 cholecystitis, pancreatitis, or malabsorption disorders (including Celiac Sprue);
 diabetes (Type 1 and Type 2)

 4. The patient or legal representative is able to understand and provide signed consent
 for the procedure.

 5. Every effort will be given to balance subjects by gender, age, and race. At least 60
 subjects from each of the 5 diagnostic groups and the 1 control group will be
 recruited.

 Control Group:

 1. Sex: Male or Female

 2. Age range: 18 to 85

 3. Freedom from qualifying medical diagnoses (control group)

 - For potential subjects for the control group, the subject is free from active
 medical diagnoses affecting the following systems or organs:

 -  Cardiovascular system: coronary artery disease, left sided congestive heart
 failure with EF <50%, valvular heart disease, atrial fibrillation, and
 hypertension

 -  Kidney: pyelonephritis, acute renal failure, or chronic renal failure stages II-V

 -  Liver: viral hepatitis, alcoholic hepatitis, steatohepatitis, or cirrhosis

 -  Pulmonary system: asthma, COPD, bronchitis, emphysema, or pneumonia

 -  Gastrointestinal/Endocrine: inflammatory bowel disease (including Crohn's
 disease, ulcerative colitis, or diverticulitis), peptic ulcer disease, IBS,
 cholecystitis, pancreatitis, or malabsorption disorders (including Celiac Sprue);
 diabetes (type 1 and type 2)

 4. The patient or legal representative is able to understand and provide signed consent
 for the procedure.

 5. Every effort will be given to balance subjects by gender, age, and race. At least 60
 subjects from each of the 5 diagnostic groups and the 1 control group will be
 recruited.

 Exclusion Criteria:

 -  Patients < 18 years in age or > 85 years in age.

 -  Inability or unwillingness to provide informed consent.

 -  Patients with pacemakers or another electrical device implanted somewhere in their
 body.

 -  Pregnant women.

 -  Patients currently undergoing therapy for cancer of any kind.